- Conditions
- Hematopoietic Cell Transplantation
- Interventions
- Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
- Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Interventions
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Influenza
- Interventions
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
- Interventions
- High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Influenza
- Interventions
- Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • San Diego, California • Vista, California + 3 more
- Conditions
- Influenza
- Interventions
- Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
- Conditions
- Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
- Interventions
- Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more
- Conditions
- Influenza
- Interventions
- FluBlok, Fluzone, FluCelVax, Fluzone HD
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Influenza, Healthy Volunteers
- Interventions
- Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
- Conditions
- Influenza, Human
- Interventions
- Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 47
- States / cities
- Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,029 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Interventions
- High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Interventions
- Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Influenza
- Interventions
- High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more